HSP90 inhibitors as therapy for multiple myeloma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue SUPPL.1, 2011, Pages

  Usmani, Saad Z ^a   Chiosis, Gabriela ^b  

^a UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Clinical trial; Heat shock protein 90; Multiple myeloma; Unfolded protein response

Indexed keywords

17AAG; 17DMAG; 5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; ALVESPIMYCIN; AT113387; AUY992; BEP800; BIIB021; BORTEZOMIB; CHAPERONE; DEXAMETHASONE; GANETESPIB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HSP90I; IPI 493; KW 2478; MPC 3100; PU H71; RAPAMYCIN; RETASPIMYCIN; SNX 2112; SNX 542; SNX 5422; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CELL CYCLE PROGRESSION; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CYTOTOXICITY; DATA ANALYSIS; DRUG DEVELOPMENT; DRUG EFFICACY; ENDOPLASMIC RETICULUM; EUKARYOTIC CELL; HUMAN; MEDICAL RECORD; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN ASSEMBLY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; SIDE EFFECT; SIGNAL TRANSDUCTION;

EID: 84860557226     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.03.027     Document Type: Conference Paper

References (37)

1. Ritossa F. A new puffing pattern induced by temperature shock and DNP in dro-sophila. Experentia 1962; 18:571-3.
2. Tissires A, Mitchell HK, Tracy U. Protein synthesis in salivary glands of Drosophila melanogaster: relation to chromosome puffs. J Mol Biol 1974; 84:389-98.
3. Csermely P, Schnaider T, Soti C, et al. The 90-kDa molecular chaperone family: structure, function, and clinical applications-a comprehensive review. Pharmacol Ther 1998; 79:129-168.
4. Zhao R, Davey M, Hsu YC, et al. Navigating the chaperone network: An integrative map of physical and genetic interactions mediated by the Hsp90 chaperone. Cell 2005; 120:715-27.
5. Rebbe NF, Ware J, Bertina RM, et al. Nucleotide sequence of acDNA for a member of the human 90kDa heat shock protein family. Gene 1987; 53:235-45.
6. Hoffmann T, Hovemann B. Heat-shock proteins, Hsp84 and Hsp86, of mice and men: two related genes encode formerly identified tumour-specific transplantation antigens. Gene 1988; 74:491-501.
7. Grammatikakis N, Vultur A, Ramana CV, et al. The Role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation. J Biol Chem 2002; 277:8312-20.
8. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004; 3:1021-30.
9. Usmani SZ, Bona RD, Li Z. 17-AAG for HSP90 inhibition in cancer-from bench to bedside. Curr Mol Med 2009; 9:654-64.
10. DeBoer C, Meulman PA, Wnuk RJ, et al. Geldanamycin, a new antibiotic. J Antibiot 1970; 23:442-7.
11. Whitesell L, Mimnaugh EG, De Costa B, et al. Inhibition of heat shock protein Hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994; 91:8324-8.
12. Supko JG, Hickman RL, Grever MR, et al. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995; 36:305-15.
13. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-deme- thoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998; 42:273-9.
14. Porter JR, Fritz CC, Depew KM. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 2010; 14:412-20.
15. Taldone T, Chiosis G. Purine-scaffold Hsp90 inhibitors. Curr Top Med Chem 2009; 9:1436-46.
16. Caldas-Lopes E, Cerchietti L, Ahn JH, et al. Hsp90 inhibitor PU-H71, a multi-modal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA 2009; 106:8368-73.
17. Cerchietti LC, Lopes EC, Yang SN, et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lym-phomas. Nat Med 2009; 15:1369-76.
18. Breinig M, Caldas-Lopes E, Goeppert B, et al. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocel-lular carcinoma. Hepatology 2009, 50:102-12.
19. Marubayashi S, Koppikar P, Taldone T, et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 2010; 120:3578-93.
20. Usmani SZ, Chiosis G, Bona RD, et al. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. J Hematol Oncol 2010; 3:40.
21. Samuel TA, Sessa C, Britten C, et al. AUY922, a novel HSP90 inhibitor: final results of a first-in-human study in patients with advanced solid malignancies.J Clin Oncol 2010; 28:2528.
22. Reddy N, Hicks D, Jagasia M, et al. SNX 2112, An oral Hsp-90 inhibitor exerts antiproliferative effects in combination with bortezomib and rituximab in ritux-imab resistant non-Hodgkin's lymphoma. Blood (abstr) 2009; 114:3733.
23. Cavenagh JD, Yong K, Byrne J, et al. The safety, pharmacokinetics and pharmaco-dynamics of KW-2478, a novel Hsp90 antagonist, in patients with B-cell malignancies: a first-in-man, phase I, multicentre, open-label, dose escalation study. Blood (abstr) 2008; 112:2777.
24. Hideshima T, Bergsagel PL, Kuehl WM, et al. Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104:607-18.
25. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006; 107:1092-100.
26. Patterson J, Palombella VJ, Fritz C, et al. IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol 2008; 61:923-32.
27. McMillin DW, Negri J, Delmore J, et al. Activity of new heat shock protein 90 (hsp90) inhibitor NVP-AUY922 against myeloma cells sensitive and resistant to conventional agents. Blood 2007; 110:1587.
28. Duus J, Bahar HI, Venkataraman G, et al. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leuk Lymphoma 2006; 47:1369-78.
29. Francis LK, Alsayed Y, Leleu X, et al. Combination mammalian target of rapa-mycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxy- geldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res 2006; 12:6826-35.
30. Okawa Y, Hideshima T, Steed P, et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis inmultiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 2009; 113:846-55.
31. Kaiser M, Lamottke B, Mieth M, et al. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. Eur J Haematol 2010; 84:337-44.
32. Stühmer T, Zöllinger A, Siegmund D, et al. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 2008; 22:1604-12.
33. Davenport EL, Moore HE, Dunlop AS, et al. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 2007; 110:2641-9.
34. Nakashima T, Ishii T, Tagaya H, et al. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin Cancer Res 2010; 16:2792-802.
35. Richardson PG, Chanan-Khan AA, Alsina M, et al. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol 2010; 150:438-45.
36. Richrdson PG, Chanan-Khan AA, Lonial S, et al. Tanespimycin + bortezomib demonstrates safety, activity, and effective target inhibition in relapsed/refractory myeloma patients: updated results of a phase 1/2 study. Blood (abstr) 2009; 114:2890.
37. Richardson PG, Badros AZ, Jagannath S, et al. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol 2010; 150:428-37.